Recurrent autosomal-dominant focal segmental glomerulosclerosis.

S. Sanna-Cherchi,D. Somenzi,M. Carnevali,F. Pilato,M. Carraro,G. Ghiggeri,L. Allegri

DOI: https://doi.org/10.1038/SJ.KI.5001796

IF: 19.6

2006-11-01

Kidney International

Abstract:

What problem does this paper attempt to address?

Effectiveness of a Pathway-Driven Ehealth-Based Integrated Care Model (PEICM) for Community-Based Hypertension Management in China: Study Protocol for a Randomized Controlled Trial

Zheyu Wang,Chengling Li,Wencai Huang,Yan Chen,Yuqiong Li,Libin Huang,Mei Zhang,Dan Wu,Li Wang,Huilong Duan,Jiye An,Ning Deng

DOI: https://doi.org/10.1186/s13063-021-05020-2

2020-01-01

Abstract:BackgroundThe prevalence of hypertension is high and increasing in China in recent years. The treatment and control of hypertension calls for long-term management beyond hospital, which is hard to implement in traditional care settings. Integrated care combined with information technology can promote high-quality healthcare services across the life-course. However, few studies have applied a customized integrated care model in community-based hypertension management in China, catering to the emerging "three-manager" mode. This study aims to identify the effectiveness of a pathway-driven eHealth-based integrated model that implemented as a full-featured telehealth system to facilitate standardized management of hypertension in China.MethodsThe trial has been designed as a 1-year, non-blinded superiority trial with two parallel groups. A total of 402 hypertensive patients who meet the eligibility criteria will be recruited and randomized with a 1:1 allocation. All the participants will receive a mobile device for self-management, which is a part of our telehealth system. Participants in the control group will only use the device for BP measurement and receive regular follow-ups from care providers according to the guidelines. Participants in the intervention group will gain full access to the system and receive intervention based on the proposed model (a well-designed coordinated care pathway consisting of 9 tasks). Outcomes will be measured mainly on three occasions (at inclusion, at 6months, and at 12months). The primary outcome is mean change in systolic blood pressure over a 12-month period. Secondary outcomes include changes in diastolic blood pressure, biochemical indexes related to hypertension, lifestyles, self-management adherence, and hypertension awareness, as well as work efficiency of care providers.DiscussionThis study aims to investigate whether a pathway-driven eHealth-based integrated care model based on the "three-manager" mode will improve hypertension control in China. Success of the model would help improve the quality of present community-based management procedures and benefit more patients with uncontrolled hypertension.Trial registrationChinese Clinical Trial Registry ChiCTR1900027645. Registered on November 22, 2019.
Evaluation of a systematic cardiovascular disease risk reduction strategy in primary healthcare: an exploratory study from Zhejiang, China.

Guanyang Zou,Xiaolin Wei,Weiwei Gong,Jia Yin,John Walley,Yunxian Yu,Zhitong Zhang,Rebecca King,Ruying Hu,Kun Chen,Min Yu

DOI: https://doi.org/10.1093/pubmed/fdu013

2015-01-01

Journal of Public Health

Abstract:In China, cardiovascular disease (CVD) risk reduction strategies are not systematically implemented in primary healthcare (PHC). We conducted an exploratory study to evaluate the preliminary effectiveness of our systematic CVD risk reduction package in one township hospital of Zhejiang. Using the Asian Equation, we selected subjects aged 40-74 years with a calculated 10-year CVD risk of 20% or higher from the existing resident health records and research checkup. The subjects were provided, as appropriate, with the low-dose combination of CVD-preventive drugs (antihypertensive drugs, aspirin, statin), lifestyle modification and adherence strategies monthly. The intervention was piloted for three months in 2012, preceding the conduct of a cluster-based randomized controlled trial (RCT). A total of 153 (40%) subjects were recruited, with an average total 10-year risk of CVD of 28.5 +/- 7.9%. After intervention, the appointment rate was up to 90%. An upward trend was observed for the use of CVD-preventive drugs. The smoking rates significantly reduced from 38 to 35%, with almost no change for salt reduction. The systolic blood pressure (BP) and diastolic BP decreased slightly. A holistic CVD risk reduction approach shows preliminary effects in a rural PHC setting of Zhejiang, China. However, further understanding is needed regarding its long-term effectiveness and feasibility in PHC practices. Our cluster-based RCT will provide the highest level of evidence for the policy development of preventing CVD in a rural PHC of China.
Rationale and design of the Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) Trial and LIGHT-ACD Trial

Jiali Song,Xiu-Ling Wang,Bin Wang,Yan Gao,Jia-Min Liu,Hai-Bo Zhang,Xi Li,Jing Li,Ji-Guang Wang,Jun Cai,Jeph Herrin,Jane Armitage,Harlan M. Krumholz,Xin Zheng

DOI: https://doi.org/10.1101/2021.03.11.21253427

2021-03-12

Abstract:Background Computerized clinical decision support systems (CDSS) are low-cost, scalable tools with the potential to improve guideline-recommended antihypertensive treatment in primary care. Uncertainty remains about the optimal initial antihypertensive therapy in the settings of real practice. Methods The Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) trial is a pragmatic, cluster-randomized controlled trial of CDSS versus usual care conducted in 100 primary care practices in China. The primary outcome is the proportion of hypertension visits with appropriate (guideline-recommended) antihypertensive treatment. Among patients recruited from primary care practices of the intervention group in the LIGHT trial, we further conducted a sub-study, the LIGHT-ACD trial, to compare the effects of initial antihypertensive therapy by randomizing individual patients to receive different antihypertensive regimens of initial monotherapy or dual therapy. The primary outcome of the sub-study is the absolute change in blood pressure from baseline to 9 months. Results We hypothesize that the use of CDSS will result in a higher proportion of appropriate antihypertensive treatments being prescribed during visits for hypertension control in the LIGHT trial, and that particular choices of monotherapy or combinations of dual therapy lead to greater blood pressure change in the LIGHT-ACD trial. Conclusion These nested trials will provide reliable evidence on the effectiveness of CDSS for improving adherence to guidelines for hypertension management in primary care, and data on the effectiveness of different initial antihypertensive regimens for blood pressure reduction. Registration number LIGHT ( NCT03636334 ) and LIGHT-ACD ( NCT03587103 ).
Cardiovascular Disease Risk Reduction in Rural China: a Clustered Randomized Controlled Trial in Zhejiang

Xiaolin Wei,Guanyang Zou,Weiwei Gong,Jia Yin,Yunxian Yu,John Walley,Zhitong Zhang,Rebecca King,Kun Chen,Marc Ka Chun Chong,Benny Chung Ying Zee,Su Liu,Jinling Tang,Sian Griffiths,Min Yu

DOI: https://doi.org/10.1186/1745-6215-14-354

IF: 2.728

2013-01-01

Trials

Abstract:Background Cardiovascular disease (CVD) is a major cause of death in China. Despite government efforts, the majority of hypertensive and diabetic patients in China do not receive proper treatment. Reducing CVD events requires long-term care that is proactive, patient-centred, community-based, and sustainable. We have designed a package of interventions for patients at high risk of CVD to be implemented by family doctors based in township hospitals (providers of primary care) in rural Zhejiang, China. This trial aims to determine whether the systematic CVD risk reduction package results in reduced CVD events among patients at risk of CVD compared with usual care, and whether the package is cost-effective and suitable for routine implementation and scale-up. Methods/Design This is a prospective, open-label, cluster randomized controlled trial (RCT) with blinded data analysis. The trial will randomize 67 township hospitals with 31,708 participants in three counties in Zhejiang Province. Participants will be identified from existing health records and will comprise adults aged 50 to 74 years, with a calculated 10-year CVD risk of 20% or higher, or diabetes. In the intervention arm, participants will receive a package of interventions including: 1) healthy lifestyle counseling (smoking cessation, and salt, oil, and alcohol reduction); 2) prescription of a combination of drugs (antihypertensives, aspirin, and statin); and 3) adherence support for drug compliance and healthy lifestyle change. In the control arm, participants will receive usual care for hypertension and diabetes management at individual clinicians’ discretion. The primary outcome is the incidence of severe CVD events over 24 months of follow-up. All CVD events will be defined according to the World Health Organization (WHO) monitoring of trends and determinants in cardiovascular disease (MONICA) definitions, diagnosed at the county hospital or higher level, and reported by the Zhejiang surveillance system. Secondary outcomes include: mean systolic and diastolic blood pressure, blood glucose, serum total cholesterol (TC), and adherence to appointments, and drugs and lifestyle changes. Discussion This trial focuses on risk reduction of CVD rather than specific diseases. It is not designed to compare therapeutic and healthy lifestyle interventions, but rather their combined effects in primary care settings. Through the trial, we intend to understand the effectiveness of the comprehensive CVD reduction package in routine practice. We also intend to understand the barriers and facilitators to implementing the package, and thus to advise on policy and practice change. Trial registration Current Controlled Trials: ISRCTN58988083
Design and rationale of the Comprehensive intelligent Hypertension managEment SyStem (CHESS) evaluation study: A cluster randomized controlled trial for hypertension management in primary care

Haibo Zhang,Xiqian Huo,Lixin Ren,Jiapeng Lu,Jing Li,Xin Zheng,Jiamin Liu,Wenjun Ma,Jing Yuan,Xiaolin Diao,Chaoqun Wu,Xiaoyan Zhang,Jin Wang,Wei Zhao,Shengshou Hu

DOI: https://doi.org/10.1016/j.ahj.2024.03.018

Abstract:Background: Hypertension management in China is suboptimal with high prevalence and low control rate due to various barriers, including lack of self-management awareness of patients and inadequate capacity of physicians. Digital therapeutic interventions including mobile health and computational device algorithms such as clinical decision support systems (CDSS) are scalable with the potential to improve blood pressure (BP) management and strengthen the healthcare system in resource-constrained areas, yet their effectiveness remains to be tested. The aim of this report is to describe the protocol of the Comprehensive intelligent Hypertension managEment SyStem (CHESS) evaluation study assessing the effect of a multifaceted hypertension management system for supporting patients and physicians on BP lowering in primary care settings. Materials and methods: The CHESS evaluation study is a parallel-group, cluster-randomized controlled trial conducted in primary care settings in China. Forty-one primary care sites from 3 counties of China are randomly assigned to either the usual care or the intervention group with the implementation of the CHESS system, more than 1,600 patients aged 35 to 80 years with uncontrolled hypertension and access to a smartphone by themselves or relatives are recruited into the study and followed up for 12 months. In the intervention group, participants receive patient-tailored reminders and alerts via messages or intelligent voice calls triggered by uploaded home blood pressure monitoring data and participants' characteristics, while physicians receive guideline-based prescription instructions according to updated individual data from each visit, and administrators receive auto-renewed feedback of hypertension management performance from the data analysis platform. The multiple components of the CHESS system can work synergistically and have undergone rigorous development and pilot evaluation using a theory-informed approach. The primary outcome is the mean change in 24-hour ambulatory systolic BP from baseline to 12 months. Discussion: The CHESS trial will provide evidence and novel insight into the effectiveness and feasibility of an implementation strategy using a comprehensive digital BP management system for reducing hypertension burden in primary care settings. Trial registration: https://www. Clinicaltrials: gov, NCT05605418.
Developing an Individualized Clinical Prediction Rules of Antihypertensive Drugs: A Study Protocol Based on Real-world Practice

Dongsheng Hong,Wendan Shi,Xiaoyang Lu,Wu Jiaying,Yan Lou,Lu Li

DOI: https://doi.org/10.1101/2020.01.29.20019364

2020-01-01

Abstract:Background Hypertension is one of the most urgent public health challenges, and drug therapy is the primary method to control blood pressure for patients. However, blood pressure control rate is still poor with antihypertensive drugs use. Although Clinical Prediction Rules (CPR) is useful to help clinicians make more appropriate decisions at the point of medication, the evidence is still limited in china. The objective of this study is to develop an CPR of antihypertensive drugs in individualized application of patients based on real-world practice. Methods A two-way cohort study has been conducted in one China’s large tertiary hospital using clinical information on patient characteristics, drug use and clinical outcome. Data extraction is through ICD-10 disease codes of hypertension from Electronic Medical Record System. Eligible patients admitted from September 2016 to August 2018 who have received at least one antihypertensive drug therapy is included. Patients were grouped into several exposure groups according to medications. COX regression model and clinical specialty survey is applied to identify Influencing Factors (IF) in different study groups, and the discriminant model was used to construct a CPR according IF. The accuracy of the CPR is analyzed by sensitivity, specificity, Youden’s index and Receiver Operating Characteristic (ROC) curve. Discussion Result is expected to provide valuable CPR for physicians and policymakers with respect to treating hypertension according characteristic of individual patients. By developing a predictive method for clinical outcomes and treatment costs of antihypertensive medication, we expect to discriminate those patients who would profit from specific scheme of antihypertensive drugs to minimal incidence probability of costs and complications in region of china. Trial registration This study was registered at [www.chictr.org][1] as a primary register of the WHO International Clinical Trials Registry Platform (ICTRP), and the registered number is ChiCTR1900026339. Highlights Although Clinical Prediction Rules (CPR) could recognize individual patient risk and help clinicians to make more appropriate decision at the point of medication as part of clinical decision support systems, the evidence in this respect is still limited in China. This study is first going to construct the CPR of multiple antihypertensive drugs in real world practice of China. The highlights of this study is aimed to provide a pragmatic method to support clinical decisions for patients who has received antihypertensive drugs before long-term diagnosis of hypertension in real world practice according to their characteristics that are accessible to clinicians. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial ChiCTR1900026339 ### Funding Statement Not applicable. ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The datasets used and/or analysis during the current study are available from the corresponding author on reasonable request. * CPR : Clinical Prediction Rules CDSS : Clinical Decision Support Systems AHD : Antihypertensive drugs (AHD) AI : Artificial intelligence IF : Influencing Factors EMRC : Electronic Medical Record System DALY : Disability-Adjusted Life Year [1]: http://www.chictr.org
Internet-based patient– primary care physician–cardiologist integrated management model of hypertension in China: study protocol for a multicentre randomised controlled trial

Runyu Ye,Rufeng Shi,Kai Liu,Xin Zhang,Si Wang,Hang Liao,Xinran Li,Qiling Gou,Xi Rong,Zhipeng Zhang,Changqiang Yang,Xiangyu Yang,Xiaoping Chen

DOI: https://doi.org/10.1136/bmjopen-2020-039447

IF: 3.006

2020-10-01

BMJ Open

Abstract:Introduction The control rate of hypertension is low in China, especially in rural, western and minority areas. This is related to poor medical skills among physicians in primary care institutions and low levels of trust among patients. However, primary healthcare institutions are the main battleground for the prevention and treatment of hypertension. It is worth exploring how to most effectively integrate patients, primary care physicians and cardiologists in tertiary hospitals, to build a long-term mechanism for the prevention and treatment of hypertension. In this study, we aim to evaluate the clinical effectiveness and conduct a health economic evaluation of an internet-based patient–primary care physician–cardiologist integrated management model of hypertension in areas of China with different socioeconomic levels. Methods and analysis This is a 12-month, multicentre, randomised controlled trial involving patients with hypertension in urban communities and rural areas of Sichuan Province, China. Each primary healthcare institution will cooperate with their tertiary hospital through the Red Shine Chronic Disease Management System (RSCDMS). Patients will be randomly assigned 1:1 to two groups: (1) a traditional care group; (2) an intervention group in which primary care physicians and cardiologists can share patient data and manage patients together through the RSCDMS. Patients can upload their blood pressure (BP) values and communicate with physicians using the system. The primary outcome is the change in systolic BP over a 12-month period. Secondary outcomes are changes in diastolic BP, BP control rate, values of 24-hour ambulatory BP monitoring, difference in cost-effectiveness between the groups, patient satisfaction, medication adherence and home BP monitoring compliance. All data will be recorded and stored in the RSCDMS and analysed using IBM SPSS V.26.0. Ethics and dissemination This study has been approved by the Biomedical Research Ethics Committee of the West China Hospital of Sichuan University in Sichuan, China (No. 2020-148). Written informed consent will be obtained from all participants. The results of this study will be disseminated to the public through academic conferences and peer-reviewed journals. Trial registration number ChiCTR2000030677.

medicine, general & internal
A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial

Yingxian Sun,Jianjun Mu,Dao Wen Wang,Nanxiang Ouyang,Liying Xing,Xiaofan Guo,Chunxia Zhao,Guocheng Ren,Ning Ye,Ying Zhou,Jun Wang,Zhao Li,Guozhe Sun,Ruihai Yang,Chung-Shiuan Chen,Jiang He,Chang Wang,Lixia Qiao,Chuning Shi,Xingang Zhang,Songyue Liu,Zihan Chen,Wei Miao,Pengyu Zhang,Zihao Fan,Nan Ye,Linlin Zhang,Danxi Geng,Shu Zhang,Qiyu Li,Qiying Qin,Canru Liu,Xiaoyu Zheng,Tao Wang,Li Jing,Boqiang Zhang,Qun Sun,Yu Yan,Yueyuan Liao,Qiong Ma,Chao Chu,Yue Sun,Dan Wang,Ling Zhou,Heng Ye,Haoran Wei,Hao Liu,Zhaoqing Sun,Liqiang Zheng,Yanli Chen,Ye Chang,Mohan Jiang,Hongmei Yang,Shasha Yu,Wenna Li,Ning Wang,Chunwei Wu,Lufan Sun,Zhi Du,Yan Li,Nan Gao,Xinchi Liu,Ying Wang,Mingang Huang,Yufang Zhou,Lingrui Meng,Jiawen Zhang,Zhen Huang,Huihui Chen,Yuxian Huang,Lingmin Sun,Xin Zhong,Hanmin Wang,Xinyan Hou,Huan Han,Baohui Jin,Hua He

DOI: https://doi.org/10.1016/s0140-6736(22)00325-7

IF: 202.731

2022-04-01

The Lancet

Abstract:BACKGROUND: The prevalence of uncontrolled hypertension is high and increasing in low-income and middle-income countries. We tested the effectiveness of a multifaceted intervention for blood pressure control in rural China led by village doctors (community health workers on the front line of primary health care).METHODS: In this open, cluster randomised trial (China Rural Hypertension Control Project), 326 villages that had a regular village doctor and participated in the China New Rural Cooperative Medical Scheme were randomly assigned (1:1) to either village doctor-led multifaceted intervention or enhanced usual care (control), with stratification by provinces, counties, and townships. We recruited individuals aged 40 years or older with an untreated blood pressure of 140/90 mm Hg or higher (≥130/80 mm Hg among those with a history of cardiovascular disease, diabetes, or chronic kidney disease) or a treated blood pressure of 130/80 mm Hg or higher. In the intervention group, trained village doctors initiated and titrated antihypertensive medications according to a standard protocol with supervision from primary care physicians. Village doctors also conducted health coaching on home blood pressure monitoring, lifestyle changes, and medication adherence. The primary outcome (reported here) was the proportion of patients with a blood pressure of less than 130/80 mm Hg at 18 months. The analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, NCT03527719, and is ongoing.FINDINGS: Between May 8 and November 28, 2018, we enrolled 33 995 individuals from 163 intervention and 163 control villages. At 18 months, 8865 (57·0%) of 15 414 patients in the intervention group and 2895 (19·9%) of 14 500 patients in the control group had a blood pressure of less than 130/80 mm Hg, with a group difference of 37·0% (95% CI 34·9 to 39·1%; p<0·0001). Mean systolic blood pressure decreased by -26·3 mm Hg (95% CI -27·1 to -25·4) from baseline to 18 months in the intervention group and by -11·8 mm Hg (-12·6 to -11·0) in the control group, with a group difference of -14·5 mm Hg (95% CI -15·7 to -13·3 mm Hg; p<0·0001). Mean diastolic blood pressure decreased by -14·6 mm Hg (-15·1 to -14·2) from baseline to 18 months in the intervention group and by -7·5 mm Hg (-7·9 to -7·2) in the control group, with a group difference of -7·1 mm Hg (-7·7 to -6·5 mm Hg; p<0·0001). No treatment-related serious adverse events were reported in either group.INTERPRETATION: Compared with enhanced usual care, village doctor-led intervention resulted in statistically significant improvements in blood pressure control among rural residents in China. This feasible, effective, and sustainable implementation strategy could be scaled up in rural China and other low-income and middle-income countries for hypertension control.FUNDING: Ministry of Science and Technology of China.

medicine, general & internal
The stresses of the surgical residency.

W. Bunch,V. Dvonch,C. Storr,D. Baldwin,P. Hughes

DOI: https://doi.org/10.1016/0022-4804(92)90046-3

IF: 2.417

1992-09-01

Journal of Surgical Research

Abstract:
Effectiveness of an impedance cardiography guided treatment strategy to improve blood pressure control in a real-world setting: results from a pragmatic clinical trial

Yuan Lu,Luyan Wang,Hongyi Wang,Jianlei Gu,Zheng J. Ma,Zheng Lian,Zhiying Zhang,Harlan Krumholz,Ningling Sun

DOI: https://doi.org/10.1136/openhrt-2021-001719

2021-01-01

Open Heart

Abstract:Objective To test the effectiveness of an impedance cardiography (ICG) guided treatment strategy on improving blood pressure (BP) control in real-world clinical practice. Design A single-centre, pragmatic randomised trial. Setting A hypertension clinic of the Peking University People's Hospital in Beijing, China. Participants Adults who sought outpatient care for hypertension in the hypertension clinic at the Peking University People's Hospital between June and December 2019. Interventions A computerised clinical decision support of recommending treatment choices to providers based on patients' haemodynamic profiles measured by ICG. Main outcome measures Changes in systolic BP (SBP) and diastolic BP (DBP) levels at the follow-up visit 4-12 weeks after baseline. Secondary outcomes included achievement of BP goal of <140/90 mm Hg and the changes in BP by baseline BP, age, sex and body mass index (BMI). Results A total of 102 adults (mean age was 54 +/- 14 years; 41% were women) completed the study. The mean baseline SBP was 150.9 (SD of 11.5) mm Hg and mean baseline DBP was 91.1 (11.3) mm Hg. At the follow-up visit, the mean SBP and DBP decreased by 19.9 and 11.3 mm Hg in the haemodynamic group, as compared with 12.0 and 4.9 mm Hg in the standard care group (p value for difference between groups <0.001). The proportion of patients achieving BP goal of <140/90 mm Hg in the haemodynamic group was 67%, as compared with 41% in the standard care group (p=0.017). The haemodynamic group had a larger effect on BP reduction consistently across subgroups by age, sex, BMI and baseline BP. Conclusions An ICG-guided treatment strategy led to greater reductions in BP levels than were observed with standard care in a real-world population of outpatients with hypertension. There is a need for further validation of this strategy for improving blood pressure treatment selection.
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial

Jiang He,Nanxiang Ouyang,Xiaofan Guo,Guozhe Sun,Zhao Li,Jianjun Mu,Dao Wen Wang,Lixia Qiao,Liying Xing,Guocheng Ren,Chunxia Zhao,Ruihai Yang,Zuyi Yuan,Chang Wang,Chuning Shi,Songyue Liu,Wei Miao,Guangxiao Li,Chung-Shiuan Chen,Yingxian Sun,Xingang Zhang,Jun Wang,Ying Zhou,Ning Ye,Zihan Chen,Pengyu Zhang,Zihao Fan,Nan Ye,Linlin Zhang,Danxi Geng,Shu Zhang,Qiyu Li,Qiying Qin,Canru Liu,Xiaoyu Zheng,Tao Wang,Li Jing,Boqiang Zhang,Qun Sun,Yu Yan,Yueyuan Liao,Qiong Ma,Chao Chu,Yue Sun,Dan Wang,Ling Zhou,Heng Ye,Haoran Wei,Hao Liu,Zhaoqing Sun,Liqiang Zheng,Yanli Chen,Ye Chang,Mohan Jiang,Hongmei Yang,Shasha Yu,Wenna Li,Ning Wang,Chunwei Wu,Lufan Sun,Zhi Du,Yan Li,Nan Gao,Xinchi Liu,Ying Wang,Mingang Huang,Yufang Zhou,Lingrui Meng,Jiawen Zhang,Zhen Huang,Huihui Chen,Yuxian Huang,Lingmin Sun,Xin Zhong,Hanmin Wang,Xinyan Hou,Huan Han,Baohui Jin,Hua He

DOI: https://doi.org/10.1016/s0140-6736(22)02603-4

IF: 202.731

2023-03-04

The Lancet

Abstract:Summary Background Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention on cardiovascular disease has not been established. We aimed to test the effectiveness of such an intervention compared with usual care on risk of cardiovascular disease and all-cause death among individuals with hypertension. Methods In this open-label, blinded-endpoint, cluster-randomised trial, we recruited individuals aged at least 40 years with an untreated systolic blood pressure of at least 140 mm Hg or a diastolic blood pressure of at least 90 mm Hg (≥130 mm Hg and ≥80 mm Hg for those at high risk for cardiovascular disease or if currently taking antihypertensive medication). We randomly assigned (1:1) 326 villages to a non-physician community health-care provider-led intervention or usual care, stratified by provinces, counties, and townships. In the intervention group, trained non-physician community health-care providers initiated and titrated antihypertensive medications according to a simple stepped-care protocol to achieve a systolic blood pressure goal of less than 130 mm Hg and diastolic blood pressure goal of less than 80 mm Hg with supervision from primary care physicians. They also delivered discounted or free antihypertensive medications and health coaching for patients. The primary effectiveness outcome was a composite outcome of myocardial infarction, stroke, heart failure requiring hospitalisation, and cardiovascular disease death during the 36-month follow-up in the study participants. Safety was assessed every 6 months. This trial is registered with ClinicalTrials.gov , NCT03527719 . Findings Between May 8 and Nov 28, 2018, we enrolled 163 villages per group with 33 995 participants. Over 36 months, the net group difference in systolic blood pressure reduction was –23·1 mm Hg (95% CI –24·4 to –21·9; p<0·0001) and in diastolic blood pressure reduction, it was –9·9 mm Hg (–10·6 to –9·3; p<0·0001). Fewer patients in the intervention group than the usual care group had a primary outcome (1·62% vs 2·40% per year; hazard ratio [HR] 0·67, 95% CI 0·61–0·73; p<0·0001). Secondary outcomes were also reduced in the intervention group: myocardial infarction (HR 0·77, 95% CI 0·60–0·98; p=0·037), stroke (0·66, 0·60–0·73; p<0·0001), heart failure (0·58, 0·42–0·81; p=0·0016), cardiovascular disease death (0·70, 0·58–0·83; p<0·0001), and all-cause death (0·85, 0·76–0·95; p=0·0037). The risk reduction of the primary outcome was consistent across subgroups of age, sex, education, antihypertensive medication use, and baseline cardiovascular disease risk. Hypotension was higher in the intervention than in the usual care group (1·75% vs 0·89%; p<0·0001). Interpretation The non-physician community health-care provider-led intensive blood pressure intervention is effective in reducing cardiovascular disease and death. Funding The Ministry of Science and Technology of China and the Science and Technology Program of Liaoning Province, China.

medicine, general & internal
Effects and Cost-Effectiveness of a Guideline-Oriented Primary Healthcare Hypertension Management Program in Beijing, China: Results from a 1-Year Controlled Trial

Xin Wang,Weiqin Li,Xian Li,Ning An,Hao Chen,Stephen Jan,Guanghua Ming,Qi Hua,Xiaowei Yan,Ningling Sun,Dong Zhao,Yangfeng Wu

DOI: https://doi.org/10.1038/hr.2012.173

2012-01-01

Hypertension Research

Abstract:Hypertension control rates are unacceptably low in China. The present study demonstrates if a customized, guideline-oriented training program can cost-effectively improve hypertension management in primary healthcare. Four typical community health centers in Beijing were selected and randomized to intervention or control (one urban and one rural each). A sample of 140 patients with hypertension and blood pressure uncontrolled was recruited from each center. Primary healthcare providers in intervention centers provided management to the recruited patients for 1 year after receiving training with customized hypertension management guidelines, and primary healthcare providers in control provided with usual care. Intention-to-treat analysis showed that hypertension control (systolic blood pressure (SBP) <140 mm Hg and diastolic blood pressure (DBP) <90 mm Hg)) rate was significantly higher in interventions than controls at month 3 (42.1% vs. 34.3% in urban and 30.7% vs. 10.0% in rural centers) and the trend increased to month 12 (70.7% vs. 40.0% in urban and 72.9% vs. 27.9% in rural); P-values by logistic mixed model were all <0.001 for both urban and rural after adjustment for baseline multiple variables including blood pressure. Mean reductions of SBP and DBP were significantly larger in interventions. The intervention was cost-saving, with an average incremental cost-saving of US$ 20.3 per patient in urban sites and $ 7.0 per patient in rural sites. Corresponding results from per-protocol analysis were very similar. The customized, guideline-oriented hypertension management program in primary healthcare in China effectively improved blood pressure control and was cost-saving.
Effect of intelligent hypertension management system on blood pressure: protocol for a randomised controlled multicentre trial

Haiyang Yu,Xiang Chen,Jiachun Xia,Lei Hou

DOI: https://doi.org/10.1136/bmjopen-2023-074580

IF: 3.006

2023-12-13

BMJ Open

Abstract:Introduction Hypertension is one of the most serious global health problems, and its prevention and treatment mainly rely on lifestyle intervention and medication. However, the current situation of hypertension control in China is still not ideal. Self-monitoring of blood pressure is expected to be a new way to control hypertension. Intervention and the Intelligent Hypertension Management System (IHMS), an information platform relying on the network and smartphone, may help patients self-monitor their blood pressure at home, allowing for intelligent management of hypertension. The aim of this trial is to investigate whether IHMS can effectively reduce blood pressure in patients with hypertension. Methods and analysis This is a multiple-centre, prospective, randomised, controlled study. 320 eligible subjects will be randomly divided into the IHMS management group (n=160) and the conventional care group (n=160). Subjects in the IHMS management group will be required to take their blood pressure daily at regular intervals at home and get treatment as directed by the IHMS; the control group will receive conventional treatment. The primary outcome of the trial is the net change in systolic blood pressure at the end point of follow-up after 3 months. The mixed-effects model will be used to compare the primary outcome that there is a greater reduction in blood pressure in the intervention group than in the control group. Ethics and dissemination The Ethics Committee of Shanghai Tongren Hospital has reviewed and approved the trial protocols, informed consent and subject information. The findings from the study will be disseminated through publications and conference presentations. The findings of the trial will be published in journals and presented at academic conferences. Trial registration number NCT05526300.

medicine, general & internal
Effectiveness of An Impedance Cardiography Guided Treatment Strategy to Improve Blood Pressure Control in A Real-World Setting: Results from A Pilot Pragmatic Clinical Trial

L. Wang,Y. Lu,H. Wang,J. Gu,Z. J. Ma,Z. Lian,Z. Zhang,H. Krumholz,N. Sun

DOI: https://doi.org/10.1101/2021.04.09.21255233

2021-01-01

MedRxiv

Abstract:Background: Hypertension is a hemodynamic-related disorder characterized by abnormalities of the cardiac output (CO) and/or systemic vascular resistance (SVR). We hypothesized that selecting antihypertensive therapy based on the hemodynamic profiles of patients could improve blood pressure (BP) control more effectively than standard care in hypertensive patients in real-world clinical practice. Methods: We conducted a pilot single-center, pragmatic randomized trial involving adults with uncontrolled hypertension who sought outpatient care at a hypertension clinic of the Peking University People Hospital, the largest teaching hospital of Peking University, in Beijing China, between December 2018 and December 2019. Participants were randomly assigned to the standard care group or the hemodynamic group in a 1:1 ratio. Impedance cardiography (ICG) was performed with all participants to measure hemodynamic parameters. Only physicians in the hemodynamic group were provided with the ICG findings of patients and a computerized clinical decision support of recommended treatment choices based on the hemodynamic profiles. The primary outcomes were the changes in systolic BP (SBP) and diastolic BP (DBP) levels at the follow-up visit 4-12 weeks after baseline. Secondary outcomes included achievement of BP goal of <140/ 90 mmHg and the changes in BP by baseline BP, age, sex, and BMI. Results: A total 102 adults (mean age was 54 (SD 14) years; 41% were women) completed the study. The mean baseline SBP was 150.9 (11.5) mmHg and mean baseline DBP was 91.1 (11.3) mmHg. At the follow-up visit, the mean SBP and DBP decreased by 19.9 and 11.3 mmHg in the hemodynamic group, as compared with 12.0 and 4.9 mmHg in the standard care group (P value for difference between groups <0.001 for both SBP and DBP). The proportion of patients achieving BP goal of <140/ 90 mmHg in the hemodynamic group was 67%, as compared with 41% in the standard care group (P=0.017). The hemodynamic group had a larger effect on BP reduction consistently across subgroups by age, sex, BMI, and baseline BP. Conclusions: An ICG-guided treatment strategy led to greater reductions in BP levels than were observed with standard care in a real-world population of outpatients with hypertension. There is a need for further validation of this strategy for improving blood pressure treatment selection. (Funded by internal research grant from the Peking University People Hospital; ClinicalTrials.gov number: NCT04715698.)
Letter: Solitary thyroid nodule.

J. E. Richardson,J. Beaugié,C. Brown

DOI: https://doi.org/10.1136/bmj.1.5908.637

1974-03-30

British Medical Journal

Abstract:SIR,-We agree with the view expressed in your leading article (10 November, p. 310) that clinically solitary thyroid nodules should be removed surgically because some are malignant. A proportion of benign follicular colloid nodules and papillary and m dullary carcinomnas can be recognized by fineneedle biopsy, but follicular carcinoma cannot be distinguished from benign adenoma by needle biopsy and here frozen section is also unreliable. Lobectomy provides the tissue necessary for diagnosis and is the d,efinitive treatment for follicular carcinomas, which have a good prognosis.' In thyroid cancer we must consider the way the disease behaves and the possible effects of each type of treatment. The behaviour of papillary, follicular, and medullary thyroid cancers, which may present as a solitary nodule, is documented in the clinicopathological classification of Hazard2 and Woolner et al.,3 which is now widely accepted. Different classifications may confuse; for example, Russell's description4 of tumour spread within the thyroid is difficult to interpret because the HazardWoolner classification was not used. If it had been, however, the descriptions given plaoe at least 80°% of his carcinomas in the papillary group. Advocates of total thyroidectomy must define their aims since the behaviour of some thyroid carcinomas is remarkably "benign." Total thyroidectomy is more radical than is usually necessary and neither removes the primary en bloc with its lymphatic drainage nor reliably ablates all thyroid tissue as a preliminary to radioiodine treatment. Of its complications, Dr. H. J. Goldsmith (5 January, p. 39) mentions hypoparathyroidism. The incidence of this reported by ex-perienced thyroid surgeons is about 150% after total thyroidectomy and we have recorded that of 12 children operated on in England and Wales in 1962-67, five have hypoparathyroidism, from which one almost died.' The condition is serious and requires life-long treatment so that only if thyroid cancers were more "malignant" might one accept this penalty. In this respect Dr. Goldsmith's analogy with prostatic cancer reflects Crile's view of some of these tumours.1-We are, etc., J. E. RICHARDSON J. M. BEAUGI9 C. L. BROWN
Integration of a multicomponent intervention for hypertension into primary healthcare services in Singapore—A cluster randomized controlled trial

Tazeen Hasan Jafar,Ngiap Chuan Tan,Rupesh Madhukar Shirore,John Carson Allen,Eric Andrew Finkelstein,Siew Wai Hwang,Agnes Ying Leng Koong,Peter Kirm Seng Moey,Gary Chun-Yun Kang,Chris Wan Teng Goh,Reena Chandhini Subramanian,Anandan Gerard Thiagarajah,Chandrika Ramakrishnan,Ching Wee Lim,Jianying Liu,for SingHypertension Study Group

DOI: https://doi.org/10.1371/journal.pmed.1004026

2022-06-14

PLoS Medicine

Abstract:Despite availability of clinical practice guidelines for hypertension management, blood pressure (BP) control remains sub-optimal (<30%) even in high-income countries. This study aims to assess the effectiveness of a potentially scalable multicomponent intervention integrated into primary care system compared to usual care on BP control. A cluster-randomized controlled trial was conducted in 8 government clinics in Singapore. The trial enrolled 916 patients aged ≥40 years with uncontrolled hypertension (systolic BP (SBP) ≥140 mmHg or diastolic BP (DBP) ≥90 mmHg). Multicomponent intervention consisted of physician training in risk-based treatment of hypertension, subsidized losartan-HCTZ single-pill combination (SPC) medications, nurse training in motivational conversations (MCs), and telephone follow-ups. Usual care (controls) comprised of routine care in the clinics, no MC or telephone follow-ups, and no subsidy on SPCs. The primary outcome was mean SBP at 24 months' post-baseline. Four clinics (447 patients) were randomized to intervention and 4 (469) to usual care. Patient enrolment commenced in January 2017, and follow-up was during December 2018 to September 2020. Analysis used intention-to-treat principles. The primary outcome was SBP at 24 months. BP at baseline, 12 and 24 months was modeled at the patient level in a likelihood-based, linear mixed model repeated measures analysis with treatment group, follow-up, treatment group × follow-up interaction as fixed effects, and random cluster (clinic) effects. A total of 766 (83.6%) patients completed 2-year follow-up. A total of 63 (14.1%) and 87 (18.6%) patients in intervention and in usual care, respectively, were lost to follow-up. At 24 months, the adjusted mean SBP was significantly lower in the intervention group compared to usual care (−3.3 mmHg; 95% CI: −6.34, −0.32; p = 0.03). The intervention led to higher BP control (odds ratio 1.51; 95% CI: 1.10, 2.09; p = 0.01), lower odds of high (>20%) 10-year cardiovascular risk score (OR 0.67; 95% CI: 0.47, 0.97; p = 0.03), and lower mean log albuminuria (−0.22; 95% CI: −0.41, −0.02; p = 0.03). Mean DBP, mortality rates, and serious adverse events including hospitalizations were not different between groups. The main limitation was no masking in the trial. A multicomponent intervention consisting of physicians trained in risk-based treatment, subsidized SPC medications, nurse-delivered motivational conversation, and telephone follow-ups improved BP control and lowered cardiovascular risk. Wide-scale implementation of a multicomponent intervention such as the one in our trial is likely to reduce hypertension-related morbidity and mortality globally. Trial Registration: Clinicaltrials.gov NCT02972619.

medicine, general & internal
[Leukocyte resistance in various leukopenias].

A. Pederzini,E. Storti

1956-12-29

Swiss Medical Weekly

Abstract:
Simplified regimen for the management of hypertension with telemedicine and blood pressure self-monitoring (SIMPLE): study protocol for a randomised controlled trial

Yao Li,Rusitanmujiang Maimaitiaili,Yi Zhang,Tienan Feng,Yawei Xu,Haotian Yang,Ji Zhang,Jia Shi,Mingliang Wang,Fang Zhao,Junqing Gao,Jun Hu,Chenghua Jiang,Yifan Zhao

DOI: https://doi.org/10.1136/bmjopen-2021-049162

IF: 3.006

2022-03-01

BMJ Open

Abstract:Introduction Telemedicine and blood pressure (BP) self-monitoring conduces to management of hypertension. Recent hypertension guidelines highly recommended single pill combination (SPC) for the initial treatment of essential hypertension. Based on this fact, an SPC-based telemedicine titration regimen with BP self-monitoring could be a better way in managing hypertension. This trial aims to elucidate whether telemedicine combined with BP self-monitoring is superior to self-monitoring alone during hypertension management. Methods and analysis This study will be a multicentred, open-labelled, randomised controlled trial. A minimum sample of 358 hypertensive patients with uncontrolled BP from four centres will be included. The intervention group will include BP self-monitoring and tele-monitoring plus a free SPC-based telemedicine titration therapy for 6 months, they will be recommended to take BP measurements at least once every 7 days, in the meantime, researchers will call to give a consultation on lifestyle or titration advice once a fortnight. The control group will be required to self-monitor BP at the same time interval as intervention group, without any therapy change. Primary outcome of the trial will be the difference in systolic blood pressure at 6-month follow-up between intervention and control group, adjusted for baseline variables. Secondary outcomes such as BP control rate, major adverse cardiovascular events, medication adherence, quality of life will be investigated. Ethics and dissemination Ethics approval was granted by Ethical Committee of Shanghai Tenth People’s Hospital (SHSY-IEC-4.1/20-194/01). The results will be disseminated in peer-reviewed literature, and to policy-makers and healthcare partners. Trial registration number ChiCTR2000037217.

medicine, general & internal
Achieving blood pressure control targets in hypertensive patients of rural China – a pilot randomized trial

Xiao Huang,Lishun Liu,Yun Song,Lan Gao,Min Zhao,Huihui Bao,Xianhui Qin,Yanqing Wu,Qinghua Wu,Chonglei Bi,Aiping Yue,Chongqian Fang,Hai Ma,Yimin Cui,Genfu Tang,Ping Li,Yan Zhang,Jianping Li,Binyan Wang,Xiping Xu,Hong Wang,Gianfranco Parati,J. David Spence,Xiaobin Wang,Yong Huo,Guangliang Chen,Xiaoshu Cheng,

DOI: https://doi.org/10.1186/s13063-020-04368-1

IF: 2.728

2020-06-11

Trials

Abstract:Abstract Background This study aimed to test the feasibility and titration methods used to achieve specific blood pressure (BP) control targets in hypertensive patients of rural China. Methods A randomized, controlled, open-label trial was conducted in Rongcheng, China. We enrolled 105 hypertensive participants aged over 60 years, and who had no history of stroke or cardiovascular disease. The patients were randomly assigned to one of three systolic-BP target groups: standard: 140 to < 150 mmHg; moderately intensive: 130 to < 140 mmHg; and intensive: < 130 mmHg. The patients were followed for 6 months. Discussion The optimal target for systolic blood pressure (SBP) lowering is still uncertain worldwide and such information is critically needed, especially in China. However, in China the rates of awareness, treatment and control are only 46.9%, 40.7%, and 15.3%, respectively. It is challenging to achieve BP control in the real world and it is very important to develop population-specific BP-control protocols that fully consider the population’s characteristics, such as age, sex, socio-economic status, compliance with medication, education level, and lifestyle. This randomized trial showed the feasibility and safety of the titration protocol to achieve desirable SBP targets (< 150, < 140, and < 130 mmHg) in a sample of rural, Chinese hypertensive patients. The three BP target groups had similar baseline characteristics. After 6 months of treatment, the mean SBP measured at an office visit was 137.2 mmHg, 131.1 mmHg, and 124.2 mmHg, respectively, in the three groups. Home BP and central aortic BP measurements were also obtained. At 6 months, home BP measurements (2 h after drug administration) showed a mean SBP of 130.9 mmHg in the standard group, 124.9 mmHg in the moderately intensive group, and 119.7 mmHg in the intensive group. No serious adverse events were recorded over the 6-month study period. Rates of adverse events, including dry cough, palpitations, and arthralgia, were low and showed no significant differences between the three groups. This trial provided real-world experience and laid the foundation for a future, large-scale, BP target study. Trial registration Feasibility Study of the Intensive Systolic Blood Pressure Control; ClinicalTrials.gov, ID: NCT02817503 . Registered retrospectively on 29 June 2016.

medicine, research & experimental
#347 Long-term effectiveness of a village doctor-led multifaceted strategy on blood pressure control: a cluster randomized trial

Jing Chen,Jiang He

DOI: https://doi.org/10.1093/ndt/gfae069.1748

IF: 7.1857

2024-05-01

Nephrology Dialysis Transplantation

Abstract:Abstract Background and Aims We tested the effectiveness of a village doctor-led multifaceted strategy on blood pressure (BP) control over 36 months among patients with hypertension in rural China. Village doctors are community health workers who provide basic primary health care in rural China. Method 326 villages were randomly assigned to the village doctor-led intervention or usual care. Individuals aged ≥40 years with an untreated mean BP ≥140/90 mmHg (≥130/80 mmHg in individuals with clinical cardiovascular disease) or treated BP ≥130/80 mmHg were recruited. The trained village doctors initiated and titrated antihypertensive medications according to a simple stepped-care protocol with supervision from primary care physicians. They also delivered discounted and free medications to patients and conducted health coaching on lifestyle change, medication adherence, and home BP monitoring. Intention to treat analysis was conducted. Results At baseline, mean age (62.8 vs. 63.2 years), percentage of women (60.9% vs. 61.6%), mean systolic BP (157.0 vs. 155.5 mmHg), and diastolic BP (88.1 vs. 87.3 mmHg) were comparable between intervention and control groups. At 36 months, 72.5% patients in the intervention group and 11.7% patients in the control group had a BP of less than 130/80 mmHg, with a group difference of 60.8% (95% CI 59.4 to 62.2%; p<0.0001). Mean systolic BP decreased by –30.8 mmHg (95% CI –31.7 to –29.9) from baseline to 36 months in the intervention group and by –7.6 mmHg (–8.5 to –6.8) in the control group, with a group difference of –23.1 mmHg (95% CI –24.4 to –21.9 mmHg; p<0.0001). Mean diastolic BP decreased by –14.8 mmHg (–15.3 to –14.3) from baseline to 36 months in the intervention group and by –4.9 mmHg (–5.3 to –4.4) in the control group, with a group difference of –9.9 mmHg (–10.6 to –9.3 mmHg; p<0.0001). No treatment-related serious adverse events were reported in either group. Conclusion In rural China, the village doctor-led multifaceted strategy significantly reduced BP over 36 months in patients with hypertension. This proven-effective and sustainable implementation strategy could be scaled up throughout rural China and in other low- and middle-income countries for hypertension control.

urology & nephrology,transplantation

Recurrent autosomal-dominant focal segmental glomerulosclerosis.

Effectiveness of a Pathway-Driven Ehealth-Based Integrated Care Model (PEICM) for Community-Based Hypertension Management in China: Study Protocol for a Randomized Controlled Trial

Evaluation of a systematic cardiovascular disease risk reduction strategy in primary healthcare: an exploratory study from Zhejiang, China.

Rationale and design of the Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) Trial and LIGHT-ACD Trial

Cardiovascular Disease Risk Reduction in Rural China: a Clustered Randomized Controlled Trial in Zhejiang

Design and rationale of the Comprehensive intelligent Hypertension managEment SyStem (CHESS) evaluation study: A cluster randomized controlled trial for hypertension management in primary care

Developing an Individualized Clinical Prediction Rules of Antihypertensive Drugs: A Study Protocol Based on Real-world Practice

Internet-based patient– primary care physician–cardiologist integrated management model of hypertension in China: study protocol for a multicentre randomised controlled trial

A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial

The stresses of the surgical residency.

Effectiveness of an impedance cardiography guided treatment strategy to improve blood pressure control in a real-world setting: results from a pragmatic clinical trial

Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial

Effects and Cost-Effectiveness of a Guideline-Oriented Primary Healthcare Hypertension Management Program in Beijing, China: Results from a 1-Year Controlled Trial

Effect of intelligent hypertension management system on blood pressure: protocol for a randomised controlled multicentre trial

Effectiveness of An Impedance Cardiography Guided Treatment Strategy to Improve Blood Pressure Control in A Real-World Setting: Results from A Pilot Pragmatic Clinical Trial

Letter: Solitary thyroid nodule.

Integration of a multicomponent intervention for hypertension into primary healthcare services in Singapore—A cluster randomized controlled trial

[Leukocyte resistance in various leukopenias].

Simplified regimen for the management of hypertension with telemedicine and blood pressure self-monitoring (SIMPLE): study protocol for a randomised controlled trial

Achieving blood pressure control targets in hypertensive patients of rural China – a pilot randomized trial

#347 Long-term effectiveness of a village doctor-led multifaceted strategy on blood pressure control: a cluster randomized trial